17383045

Source:http://linkedlifedata.com/resource/pubmed/id/17383045

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0022671, umls-concept:C0030705, umls-concept:C0035525, umls-concept:C0087111, umls-concept:C0391001, umls-concept:C0524910
pubmed:issue	5
pubmed:dateCreated	2007-4-10
pubmed:abstractText	We undertook a pilot study to investigate the efficacy and safety of peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed chronic HCV patients awaiting renal transplant.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/17383045-18644649
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8503886
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents, http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha, http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols, http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin, http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2a, http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2a
pubmed:status	MEDLINE
pubmed:month	May
pubmed:issn	0168-8278
pubmed:author	pubmed-author:AmorusoAnna CinziaAC, pubmed-author:CastellanetaNicola MaurizioNM, pubmed-author:Di LeoAlfredoA, pubmed-author:FrancavillaAntonioA, pubmed-author:LositoFrancescoF, pubmed-author:RendinaMariaM, pubmed-author:SchenaAntonioA, pubmed-author:SchenaFrancesco PaoloFP, pubmed-author:StalloneGiovanniG
pubmed:issnType	Print
pubmed:volume	46
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	768-74
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:17383045-Adult, pubmed-meshheading:17383045-Antiviral Agents, pubmed-meshheading:17383045-Drug Therapy, Combination, pubmed-meshheading:17383045-Female, pubmed-meshheading:17383045-Follow-Up Studies, pubmed-meshheading:17383045-Hepacivirus, pubmed-meshheading:17383045-Hepatitis C, Chronic, pubmed-meshheading:17383045-Humans, pubmed-meshheading:17383045-Injections, Subcutaneous, pubmed-meshheading:17383045-Interferon-alpha, pubmed-meshheading:17383045-Kidney Failure, Chronic, pubmed-meshheading:17383045-Kidney Transplantation, pubmed-meshheading:17383045-Male, pubmed-meshheading:17383045-Middle Aged, pubmed-meshheading:17383045-Pilot Projects, pubmed-meshheading:17383045-Polyethylene Glycols, pubmed-meshheading:17383045-Preoperative Care, pubmed-meshheading:17383045-RNA, Viral, pubmed-meshheading:17383045-Recombinant Proteins, pubmed-meshheading:17383045-Renal Dialysis, pubmed-meshheading:17383045-Ribavirin, pubmed-meshheading:17383045-Treatment Outcome
pubmed:year	2007
pubmed:articleTitle	The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant.
pubmed:affiliation	Department of Emergency and Organ Transplantation, Section of Gastroenterology, University of Bari, Piazza G. Cesare 11, 70124 Bari, Italy.
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't